Ibrutinib: all 284 studies that test it
Page 2 of 3. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell LymphomaTerminatedNCT02272686Phase 2Results posted
- A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLCompletedNCT02268851Phase 1Results posted
- A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)CompletedNCT02264574Phase 3Results posted
- A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
- Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell LymphomaCompletedNCT02242097Phase 2Results posted
- Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin LymphomaCompletedNCT02207062Phase 2Results posted
- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host DiseaseCompletedNCT02195869Phase 1/2Results posted
- Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaCompletedNCT02165397Phase 3Results posted
- Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaTerminatedNCT02129062Phase 2Results posted
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02077166Phase 1/2Results posted
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT02048813Phase 3Results posted
- Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2Results posted
- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone LymphomaCompletedNCT01980628Phase 2Results posted
- A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin LymphomaCompletedNCT01974440Phase 3Results posted
- A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/LymphomaCompletedNCT01973387Phase 3Results posted
- Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT01962792Phase 1/2Results posted
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT01886872Phase 3Results posted
- A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaCompletedNCT01855750Phase 3Results posted
- Ibrutinib in Treating Patients With Relapsed or Refractory Follicular LymphomaActive, not recruitingNCT01849263Phase 2Results posted
- A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT01776840Phase 3Results posted
- Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLLCompletedNCT01752426Phase 1/2Results posted
- A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p DeletionCompletedNCT01744691Phase 2Results posted
- Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01724346Phase 3Results posted
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLLCompletedNCT01722487Phase 3Results posted
- Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyCompletedNCT01646021Phase 3Results posted
- Ibrutinib (PCI-32765) in Waldenstrom's MacroglobulinemiaCompletedNCT01614821Phase 2Results posted
- A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01611090Phase 3Results posted
- PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic LeukemiaActive, not recruitingNCT01589302Phase 2Results posted
- A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01578707Phase 3Results posted
- Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma PatientsCompletedNCT01520519Phase 2Results posted
- PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT01500733Phase 2Results posted
- Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT01325701Phase 2Results posted
- Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01292135Phase 1Results posted
- Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01236391Phase 2Results posted
- Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLLCompletedNCT01217749Phase 1/2Results posted
- Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01109069Phase 2Results posted
- Safety of PCI-32765 in Chronic Lymphocytic LeukemiaCompletedNCT01105247Phase 1/2Results posted
- Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantTerminatedNCT06271616Phase 2
- Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationActive, not recruitingNCT05672173Phase 2
- Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host DiseaseStatus unknownNCT05348096Phase 2
- A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;CompletedNCT04939363Phase 2
- A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLLCompletedNCT04876092Phase 1
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
- Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLWithdrawnNCT04685915Phase 2
- Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)WithdrawnNCT04665115Phase 2
- CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.Active, not recruitingNCT04639362Phase 2
- Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)Active, not recruitingNCT04608318Phase 3
- PRECISE CURATE.AI Pilot Clinical TrialStatus unknownNCT04522284Phase 1/2
- Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS LymphomaStatus unknownNCT04514393Phase 2
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
- Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaActive, not recruitingNCT04450173Phase 2
- LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)Active, not recruitingNCT04446962Phase 1/2
- Ibrutinib for the Treatment of COVID-19 in Patients Requiring HospitalizationCompletedNCT04439006Phase 1
- The Safety and Efficacy of Ibrutinib in Refractory/Relapsed Autoimmune Hemolytic AnemiaActive, not recruitingNCT04398459Phase 2
- A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4CompletedNCT04274738Phase 1
- Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's MacroglobulinemiaActive, not recruitingNCT04263480Phase 2
- Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT04234061Phase 2
- ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
- Biomarker Guided Treatment in DLBCLStatus unknownNCT04025593Phase 2
- Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic LeukemiaCompletedNCT04010968Phase 2
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCLActive, not recruitingNCT03960840Phase 1/2
- Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCLStatus unknownNCT03949062Phase 2
- Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib ResistanceWithdrawnNCT03943342Phase 2
- Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaCompletedNCT03939182Phase 1
- Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedNCT03876028Phase 1
- Ibrutinib in Steroid Refractory Autoimmune Hemolytic AnemiaStatus unknownNCT03827603Phase 2
- Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)CompletedNCT03790332Phase 1/2
- Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2
- Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic LeukemiaCompletedNCT03755947Phase 2
- Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 DysfunctionActive, not recruitingNCT03734198Phase 2
- Ibrutinib + R-CHOP Followed by Ibrutinib MaintenanceActive, not recruitingNCT03731234Phase 2
- Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLLTerminatedNCT03708003Phase 2
- Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)CompletedNCT03703167Phase 1
- MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone LymphomasActive, not recruitingNCT03697512Phase 2
- Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AMLStatus unknownNCT03642236Phase 2/3
- Efficacy of First Line B-RI for Treatment Naive Waldenström's MacroglobulinemiaActive, not recruitingNCT03620903Phase 2
- Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell LymphomaWithdrawnNCT03617484Phase 2
- Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)CompletedNCT03581942Phase 1/2
- Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid TumorsCompletedNCT03525925Phase 1
- Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance MutationsActive, not recruitingNCT03513562Phase 2
- Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaActive, not recruitingNCT03479268Phase 1
- Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT03478514Phase 2
- A Study of BNC105P Combined With IbrutinibCompletedNCT03454165Phase 1
- Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT03447808Phase 1
- Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell LymphomaCompletedNCT03440567Phase 1
- INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
- Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent IbrutinibActive, not recruitingNCT03422393Phase 1
- Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell LymphomaCompletedNCT03399513Phase 2
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast CancerActive, not recruitingNCT03379428Phase 1/2
- Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromeCompletedNCT03359460Phase 1
- A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell MalignancyCompletedNCT03301207Phase 1
- Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell LymphomaActive, not recruitingNCT03282396Phase 2
- Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With OfatumumabStatus unknownNCT03280160Phase 2
- Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT03232307Phase 2
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.Active, not recruitingNCT03229200Phase 4
- Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell LymphomaCompletedNCT03219047Early Phase 1
- Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)Active, not recruitingNCT03153202Phase 1/2
- Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain AmyloidosisWithdrawnNCT03130348Phase 2
- Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2CompletedNCT03129828Phase 1/2
- Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLLActive, not recruitingNCT03128879Phase 2